FDA admits that the agency’s response to the baby-hormula shortage was too slow

By Stephanie Armour of The WSJ. Excerpt:

"The shortage that hit in the spring was driven by a number of factors, including supply-chain problems triggered by the pandemic and the voluntary recall of some products by Abbott. The company temporarily closed a plant in Sturgis, Mich., where its Similac infant formula was produced. The plant reopened in August.

The FDA responded by temporarily letting foreign manufacturers ship their products to the U.S. FDA Commissioner Robert Califf commissioned an external review of the agency’s food division, saying in congressional testimony that the agency’s response to the shortage was too slow."